Cargando…

Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone

Schizophrenia is a common disease managed by a range of interventions, with the primary treatment being antipsychotic medications (APS). Inadequate response, lack of adherence, and/or adverse events often prevent optimal therapeutic effects or therapeutic efficiency. Monitoring APS plasma concentrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korell, J, Green, B, Remmerie, B, Vermeulen, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613178/ https://www.ncbi.nlm.nih.gov/pubmed/28614899 http://dx.doi.org/10.1002/psp4.12217

Ejemplares similares

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole
por: Remmerie, Bart, et al.
Publicado: (2016)

Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole
por: Remmerie, Bart, et al.
Publicado: (2016)

Comparative Pharmacology of Risperidone and Paliperidone
por: Corena-McLeod, Maria
Publicado: (2015)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

Audit on prolactin monitoring for patients on oral risperidone, intramuscular risperidone, and intramuscular paliperidone
por: Bader, Mohamed
Publicado: (2021)

Optimizing Antipsychotic Patient Management Using Population Pharmacokinetic Models and Point‐of‐Care Testing
por: Green, B, et al.
Publicado: (2017)

Evidence based administration of risperidone and paliperidone for the treating conduct disorder
por: Ghanizadeh, Ahmad
Publicado: (2013)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
por: Turkoz, Ibrahim, et al.
Publicado: (2011)

S56. SWITCHING FROM RISPERIDONE TO PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: CHANGES IN COGNITIVE FUNCTION
por: Tost Bonet, Meritxell, et al.
Publicado: (2020)

Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia
por: Wu, Rong-Qin, et al.
Publicado: (2018)

Pharmacokinetic-Pharmacodynamic Modeling of the D(2) and 5-HT(2A) Receptor Occupancy of Risperidone and Paliperidone in Rats
por: Kozielska, Magdalena, et al.
Publicado: (2012)

Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes
por: Hsia, Stephanie L., et al.
Publicado: (2018)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
por: Voss, Erica A., et al.
Publicado: (2015)

Tachycardia during Treatment with Risperidone and Paliperidone Palmitate in a Patient without Previous Cardiovascular Disease
por: Orlins, Zachary, et al.
Publicado: (2021)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
por: Patel, Charmi, et al.
Publicado: (2020)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
por: Zhao, Mingjun, et al.
Publicado: (2023)

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
por: Samtani, Mahesh N, et al.
Publicado: (2013)

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models
por: Boyda, Heidi N., et al.
Publicado: (2021)

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics
por: Schreiner, A, et al.
Publicado: (2015)

Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients
por: Wang, Gang, et al.
Publicado: (2020)

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium
por: Cai, Rui, et al.
Publicado: (2022)

Physiologically‐based pharmacokinetic model to investigate the effect of pregnancy on risperidone and paliperidone pharmacokinetics: Application to a pregnant woman and her neonate
por: Mahdy, Walaa Y. B., et al.
Publicado: (2023)

Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder
por: Kloosterboer, Sanne Maartje, et al.
Publicado: (2020)

Two cases of life‐threatening arrhythmia induced by risperidone: evaluation of risperidone and 9‐hydroxy‐risperidone concentrations
por: Ito, Asami, et al.
Publicado: (2017)

Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia
por: Shimizu, Hiroko, et al.
Publicado: (2019)

Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France
por: Limosin, Frédéric, et al.
Publicado: (2018)

Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations
por: Russu, Alberto, et al.
Publicado: (2018)

Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
por: Alphs, Larry, et al.
Publicado: (2011)

Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D(2) receptor antagonists risperidone, paliperidone and remoxipride in rats
por: Taneja, Amit, et al.
Publicado: (2016)

Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone
por: Lu, Jinjun, et al.
Publicado: (2021)

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in france, germany and belgium – a retrospective database study
por: Cai, R., et al.
Publicado: (2021)

Total bilirubin in athletes, determination of reference range
por: Witek, K, et al.
Publicado: (2016)

Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
por: Takekita, Yoshiteru, et al.
Publicado: (2016)

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
por: Coppola, Danielle, et al.
Publicado: (2012)

Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports
por: Hodkinson, Alexander, et al.
Publicado: (2021)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

Correlation of hair risperidone concentration and serum level among patients with schizophrenia
por: Sun, Xiujia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8t0fm3ot6318mgd3068ctvlkb1